{"id":"intramuscular-aripiprazole-olanzapine","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Weight gain"},{"rate":"15-25","effect":"Sedation"},{"rate":"10-20","effect":"Akathisia"},{"rate":"5-15","effect":"Extrapyramidal symptoms"},{"rate":"15-25","effect":"Metabolic syndrome"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-10","effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole acts as a dopamine D2 receptor partial agonist and serotonin 5-HT1A partial agonist, while olanzapine is a dopamine D2 and serotonin 5-HT2A receptor antagonist. Both agents work through different mechanisms but converge on reducing hyperactivity in mesolimbic and mesocortical dopamine pathways implicated in psychosis, while the intramuscular formulation provides sustained therapeutic levels for improved medication adherence in patients with schizophrenia or bipolar disorder.","oneSentence":"Aripiprazole and olanzapine are atypical antipsychotics that modulate dopamine and serotonin signaling in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:35.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia (maintenance treatment via intramuscular injection)"},{"name":"Bipolar I disorder (maintenance treatment via intramuscular injection)"}]},"trialDetails":[{"nctId":"NCT00895921","phase":"PHASE4","title":"Examining the Effects of Antipsychotic Medications on Insulin Sensitivity","status":"COMPLETED","sponsor":"Veterans Medical Research Foundation","startDate":"2008-11","conditions":"Diabetes","enrollment":30},{"nctId":"NCT01411930","phase":"PHASE4","title":"Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics","status":"COMPLETED","sponsor":"Veterans Medical Research Foundation","startDate":"2009-03","conditions":"Diabetes","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aripiprazole -> Olanzapine"],"phase":"marketed","status":"active","brandName":"Intramuscular aripiprazole, olanzapine","genericName":"Intramuscular aripiprazole, olanzapine","companyName":"Veterans Medical Research Foundation","companyId":"veterans-medical-research-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole and olanzapine are atypical antipsychotics that modulate dopamine and serotonin signaling in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia (maintenance treatment via intramuscular injection), Bipolar I disorder (maintenance treatment via intramuscular injection).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}